NIKKEI 225
26,215.79 +278.58 (+1.07%) HANG SENG
17,079.51 -143.32 (-0.83%) CRUDE OIL
82.88 +3.39 (+4.26%) GOLD FUTURES
1,701.80 +29.80 (+1.78%) DOW
29,350.91 +625.40 (+2.18%) BTC-GBP
17,197.96 +103.05 (+0.60%)
MorphoSys AG (MOR.DE)
| Previous close | 20.56 |
| Open | 20.25 |
| Bid | 20.74 x 1500 |
| Ask | 20.79 x 8800 |
| Day's range | 19.60 - 21.07 |
| 52-week range | 16.08 - 43.29 |
| Volume | |
| Avg. volume | 197,200 |
| Market cap | 710.474M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 7.00 |
| EPS (TTM) | 2.97 |
| Earnings date | 16 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.36 |
- EQS Group
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOSTON, Mass., USA, September 28, 2022 MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R D
- EQS Group
MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2022 MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte PetersTim Demuth, M.D., Ph.D., has more than 20 years of broad leade
- Motley Fool
MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript
At this time, I would like to turn the conference over to Julia Neugebauer. My name is Julia Neugebauer, head of investor relations at MorphoSys, and it is my pleasure to welcome you to our half year 2022 financial results conference call. With me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.
